HTG Molecular Diagnostics
HTG Molecular Diagnostics is a Tucson-based public company that develops proprietary assays and reagent systems for gene expression analysis, serving research and clinical laboratories. The company filed Chapter 11 in 2023 and now trades on the PNK exchange.
- Company typePublic
- Founded1997
- HeadquartersTucson, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What HTG Molecular Diagnostics does
HTG Molecular Diagnostics is a Tucson, Arizona-based molecular diagnostics company that develops assays and reagent systems for gene expression analysis, serving research and clinical laboratory customers. Founded in 1997, the company was historically a public entity (NASDAQ: HTGM) and raised over $100 million in equity capital across more than a decade from investors including Oxford Finance, Silicon Valley Bank, Merck Capital Ventures, Novo Holdings, SR One, and others. Its core technology is a proprietary chemistry- and reagent-based platform that enables gene expression profiling, with management-led commercialization efforts directed at biopharma, translational research, and clinical lab users. The company is led by John Lubniewski (President and CEO) with Bruce Seligmann as CSO and a small executive team.
The company's revenue model historically centered on selling assay kits, reagent systems, and associated services to laboratory customers, though no current pricing or revenue figures are disclosed in available materials. The business has been in acute financial distress: HTG raised approximately $10 million through a public offering in December 2022 to fund clinical trials and operating expenses, but filed for Chapter 11 bankruptcy in 2023. The common stock now trades on the OTC PNK exchange under ticker HTGMQ, with a market capitalization of roughly $221 and a negative EPS of -16.83, against a 1.55 debt-to-equity ratio. The corporate website has effectively lapsed, currently displaying an unrelated Swedish online-casino affiliate page, indicating a collapse in basic digital infrastructure post-bankruptcy. The company's ownership structure and customer base post-restructuring are not disclosed in available sources.
HTG Molecular Diagnostics firmographics
Firmographics- Name
- HTG Molecular Diagnostics
- Legal name
- HTG Molecular Diagnostics
- Website
- https://htgmolecular.com
- Company type
- Public
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- HTG Molecular Diagnostics is a Tucson-based public company that develops proprietary assays and reagent systems for gene expression analysis, serving research and clinical laboratories. The company filed Chapter 11 in 2023 and now trades on the PNK exchange.
- Ownership category
- akta.pro rank
HTG Molecular Diagnostics industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
- akta.pro secondary industries
- Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)
Keywords
Where HTG Molecular Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Tucson
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
HTG Molecular Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
HTG Molecular Diagnostics product offering
Product offeringCore offering
HTG Molecular Diagnostics develops and manufactures molecular diagnostic assays and reagent systems used for gene expression analysis. Its products enable researchers and clinicians to profile RNA expression from biological samples, supporting biomarker discovery, translational research, and clinical diagnostic applications. The company's core business centers on the sale of proprietary assay kits and related reagent consumables.
Differentiator
Problem solved
Functional benefit
Products and services
- HTG Gene Expression Assay Kits and Reagent Systems
- Custom Assay Development Services
Companies that use HTG Molecular Diagnostics
Customer profileIdeal customer profiles2 records
HTG Molecular Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
HTG Molecular Diagnostics partnerships and signals
Strategic signalScale indicators5 records
Recent moves5 records
Expansion highlights2 records
HTG Molecular Diagnostics competitors and assessment
Company assessmentDirect peers
- NanoString Technologies: Direct peer specializing in gene expression analysis and spatial transcriptomics, offering RNA profiling assays and instruments that overlap directly with HTG's molecular diagnostics reagent and assay portfolio.
- Standard BioTools (formerly Fluidigm): Develops mass cytometry and gene expression tools for life sciences research, including transcriptomic and targeted profiling assays that compete with HTG's gene expression reagent systems.
- Luminex (acquired by DiaSorin): Multi-analyte profiling and molecular diagnostics reagents (now under DiaSorin) directly overlap with HTG's assay/reagent business for gene expression and biomarker profiling.
Broad incumbents
- Bio-Rad Laboratories: Broad life sciences tools and molecular diagnostics incumbent offering PCR, digital PCR, and gene expression reagents — overlapping with HTG's assay business as part of a much larger product portfolio.
- Qiagen: Established molecular diagnostics and sample technologies company with broad RNA/DNA extraction, assay, and PCR offerings; competes with HTG in gene expression and molecular sample-prep workflows.
- Thermo Fisher Scientific: Diversified life sciences giant with substantial molecular diagnostics, gene expression reagents, and analytical instrument portfolios covering nearly every segment where HTG operates.
- PerkinElmer (now Revvity): Provides diagnostics and life sciences tools including gene expression, genomics, and reagent kits that overlap with HTG's profiling assay offering across research and clinical markets.
- Illumina: Dominant sequencing and molecular diagnostics platform with gene expression products (e.g., RNA-seq, targeted panels); competes with HTG's gene expression assay business as a broad incumbent.
- Myriad Genetics: Molecular diagnostics company with gene expression and biomarker testing capabilities serving clinical and pharma customers, comparable in target end-market though focused more on clinical tests than research assays.
- Agilent Technologies: Major life sciences and diagnostics tools provider offering gene expression microarrays, qPCR, and analytical instruments that overlap with HTG's molecular profiling reagent and assay portfolio.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
HTG Molecular Diagnostics social profiles
Digital presenceHTG Molecular Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
HTG Molecular Diagnostics leadership team
Management profileNumber of profiles
Profiles7 records
HTG Molecular Diagnostics funding detail
Funding detailFunding overview
Funding rounds14 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HTG Molecular Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HTG Molecular Diagnostics
What does HTG Molecular Diagnostics do?
HTG Molecular Diagnostics develops and manufactures molecular diagnostic assays and reagent systems used for gene expression analysis. Its products enable researchers and clinicians to profile RNA expression from biological samples, supporting biomarker discovery, translational research, and clinical diagnostic applications. The company's core business centers on the sale of proprietary assay kits and related reagent consumables.
Is HTG Molecular Diagnostics a public or private company?
HTG Molecular Diagnostics is a public company. It is classified as public and is currently operating.
When was HTG Molecular Diagnostics founded?
HTG Molecular Diagnostics was founded in 1997. It employs 51 to 100 people.
Where is HTG Molecular Diagnostics based?
HTG Molecular Diagnostics is headquartered in Tucson, United States, in the North America region.
Who are HTG Molecular Diagnostics's main competitors?
Direct peers on record are NanoString Technologies, Standard BioTools (formerly Fluidigm) and Luminex (acquired by DiaSorin). Broad incumbents are Bio-Rad Laboratories, Qiagen, Thermo Fisher Scientific, PerkinElmer (now Revvity), Illumina, Myriad Genetics and Agilent Technologies.
Does HTG Molecular Diagnostics have an API?
No public API is recorded for HTG Molecular Diagnostics.
What industry is HTG Molecular Diagnostics in?
HTG Molecular Diagnostics's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 325413 and its SIC code is 2835.